New combo aims to halt ovarian Cancer's return
NCT ID NCT04387227
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 29 times
Summary
This study tests whether combining an immunotherapy drug (pembrolizumab) with chemotherapy (carboplatin) can prevent ovarian, fallopian tube, or peritoneal cancer from progressing after a blood test shows it may be coming back. About 22 adults whose cancer had previously responded to treatment but now shows signs of return (via CA-125 levels) but no visible tumors on scans will receive the drug combo. The goal is to delay or stop the cancer from becoming detectable on imaging.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.